moderna inc məˈdɜːrnə pharmaceutical biotechnology company based cambridge massachusetts focuses rna therapeutics primarily mrna vaccines vaccines use copy molecule called messenger rna mrna carry instructions proteins produce immune companys name derived terms modified rna companys commercial product moderna vaccine marketed spikevax company treatment vaccine candidates entered clinical trials candidates include possible vaccines influenza hiv respiratory syncytial virus virus nipah virus chikungunya human metapneumovirus varicella zoster virus well cytomegalovirus vaccine zika virus vaccine funded biomedical advanced research development authority three cancer vaccines companys pipeline also includes cell therapybased treatment relaxin fusion protein developed treat acute decompensated heart failure also includes candidates use ligand interleukin interleukin cancer immunotherapy specifically treatment breast cancer urothelial carcinoma lymphoma melanoma also developed moderna regenerative medicine treatment encodes vascular endothelial growth factor stimulate blood vessel growth patients myocardial moderna founded derrick rossi timothy springer kenneth r chien robert langer noubar stéphane bancel current ceo appointed ceo moderna raised billion venture capital company formed partnership astrazeneca develop treatments cardiovascular metabolic renal diseases well cancer january company entered agreement alexion pharmaceuticals develop treatments ten january moderna announced creation first venture onkaido therapeutics focus exclusively developing mrnabased oncology launched second venture valera january focus viral bacterial parasitic infectious employees valera moderna developed mrna vaccine candidate zika virus another venture elpidera announced may continue work rna therapies advancing modernas work company formed partnership merck co develop treatments cancer company formed partnership vertex pharmaceuticals develop treatments cystic january bill melinda gates foundation committed provide least million grant funding alexion terminated partnership moderna safety issues prevented work reaching human july company opened square foot facility norwood massachusetts manufacturing preclinical clinical december moderna became public company via largest initial public offering biotechnology company history raising million selling million shares per first mrna vaccine developed moderna influenza first antibody encoded mrna moderna acquired oriciro genomics japanese manufacturer genetic engineering tools first early company collaboration merck breakthrough status fda drug candidate cancer july company entered agreement chinese government develop mrna drugs exclusive use moderna received million operation warp speed accelerate development vaccine billion committed total producing million vaccine march food drug administration approved clinical trials moderna vaccine candidate december vaccine issued emergency use authorization united gained fda approval monovalent vaccine spikevax bivalent april moderna announced plans build million vaccine factory montreal forming partnership government canada quebec mcgill university produce million spikevax doses annually expand vaccine research february company agreed pay million national institutes health dartmouth college scripps research settle dispute rights chemical technique used april court affirmed decision cancel patent arbutus biopharma patent dispute moderna regarding several legal cases moderna pfizer biontech various countries alleging vaccine violates patent modernas mrna vaccine technology httpsenwikipediaorgwikimoderna